Integrity BMS    

Log In

Forgot Your Password?

Not a member? Click here!

AiMI: AngioJet Rheolytic Thrombectomy In Patients Undergoing Primary Angioplasty for Acute MI
Harmonization of the European and the US Experience with the New Requirements
Long-Term Outcomes of Coronary-Artery Bypass Grafting versus Stent Implantation
Management of SVG Disease
Persistent Left Superior Vena Cava



How Common Is Prosthetic Aortic Leaflet Thrombosis?

Reduced prosthetic aortic leaflet mobility (RPALM) may be an indicator of subclinical leaflet thrombosis. A study of 55 patients from a TAVR trial and 132 patients from two single-center registries has reported that RPALM was noted in 40% of the clinical trial cohort and 13% of the registry cohort. RPALM was shown to be reduced with the use of oral anticoagulation, and in the registry cohort, RPALM was associated with increased risk of TIA and stroke.

For more, click here




Polymer Free DES in High Bleeding Risk Patients

The utility of DES in patients at high risk of bleeding is limited due to the required antiplatelet therapy period. The LEADERS FREE investigators examined the safety and efficacy of a polymer-free and carrier-free dug-coated stent (biolimus A9) as compared to a BMS in such a cohort. In a cohort of 2466 patients, the biolimus A9 was shown to be superior to a BMS with regard to safety and efficacy when used with a 1-month course of DAPT.

For more, click here



The Challenge of ISR Therapy

In-stent restenosis (ISR) and its therapy continue to pose a major challenge for interventional cardiology. A network meta-analysis has demonstrated that balloon angioplasty is inferior to drug-eluting treatments while paclitaxel-eluting cutting balloon, everolimus-eluting stent and paclitaxel-eluting balloon were among the best treatment modalities based upon low TLR.

For more, click here




Spironolactone for Resistant Hypertension

The optimal medical therapy for resistant hypertension remains elusive. In a double-blind, placebo-controlled, cross-over trial involving 14 UK centers, spironolactone was found to be the most effective add-on drug in patients with resistant hypertension as compared to bisoprolol or doxazosin.

For more, click here



First-in-man Experience of the Transcatheter FORMA Repair System for Treating Severe Tricuspid Regurgitation
- Francisco Campelo-Parada, MD
Selecting the Right FFR in an Unsteady State: Keep It Simple
- Morton Kern, MD
Transcatheter Structural Heart Interventions for the treatment of Chronic Heart Failure
- Dr Josep Rodes Cabau, MD
The Third DANish Study of Optimal Acute Treatment of Patients with ST-segment Elevation Myocardial Infarction
- Thomas Engstrøm, MD, DMSci, PhD
Relationship between hospital PTCA volume and in-hospital outcomes: Is it still true 9 years later?
- Christian Spaulding, M.D., FACC, FESC
The EGO-BioFreedom Study
- Stephen Lee, MD
Prosthesis-Patient Mismatch in High Risk Patients with Severe Aortic Stenosis in a Randomized Trial of a Self-Expanding Prosthesis
- George L. Zorn, III, MD
The Risk and Extent of Neurological Events Are Equivalent for High-Risk Patients Treated With Transcatheter or Surgical Aortic Valve Replacement
- Thomas G. Gleason, MD
Valve Thrombosis After TAVR: Frequency, Clinical Recognition, and Management
- Azeem Latib, MD
 Click here to visit the WEBEX archives
Complex Patients Today and Tomorrow: Medtronic DES solutions from Resolute Integrity to bioresorbable stents
Prof. Sigmund Silber, MD
First Report on the Pivotal DESolve Nx trial: 6-month Clinical and Multimodality Imaging Results
Alexandre Abizaid, MD, PhD
One-Year Outcomes in 1010 Unselected Patients Treated with the PROMUS Element Everolimus-Eluting Stent: The Multicenter PROMUS Element European Post-Approval Surveillance Study
Raul Moreno, MD, et al.
Two-year clinical outcomes in the EVOLVE FHU trial
Ian Meredith, MD, PhD
Stephan Windecker, MD, et al.

Durable Polymer DES: 5 Year Outcomes RESOLUTE Update
Sigmund Silber, MD
Evaluation of Two-Year Outcomes Following Resolute Integrity Zotarolimus-eluting Stent Implantation
Ronald Caputo, MD
Properties of a Novel Drug Filled Coronary Stent: Impact on Mechanical Strength and Radiopacity
Nicolas Foin, MSc, PhD
Titratable Drug Delivery from Drug-Filled Stents
Rami Tzafriri, MD
Outcomes in More Than 7000 Patients With Diabetes After Implantation of the Resolute Zotarolimus-eluting Stent
Rosli Mohd Ali, MD
Safety update and long-term clinical outcomes from all studies in the RESOLUTE Global Clinical Program
Carlo Di Mario, MD
Final Five-year Outcomes from the Randomized Comparison of Zotarolimus-eluting Stents With Everolimus-eluting Stents in the RESOLUTE All Comers Trial
Stephan Windecker, MD
Angina Status & TLF Creep: Bioabsorbable Stents (BAS) & Drug-Eluting Stents (DES)
Medtronic, Inc.
Clinical outcomes associated with dual antiplatelet therapy interruption following implantation of the ResoluteTM zotarolimus-eluting stent
Stephan Windecker, MD
Four-year Outcomes from the Randomized Comparison of a Zotarolimus-eluting and an Everolimus-eluting Stent in the RESOLUTE All Comers Trial
Patrick W Serruys MD, PhD
Resolute in Bifurcation Lesions: Data from the RESOLUTE Clinical Program
Prof. Ran Kornowski, MD

Untitled Document
Efficacy and Safety of Vorapaxar With and Without a Thienopyridine for Secondary Prevention in Patients With Previous Myocardial Infarction and No History of Stroke or Transient Ischemic Attack. Results from TRA 2°P-TIMI 50.
E Bohula, et al.
Circ 2015; 132:1871-1879
Sulodexide for the Prevention of Recurrent Venous Thromboembolism. The Sulodexide in Secondary Prevention of Recurrent Deep Vein Thrombosis (SURVET) Study: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial.
G Andreozzi, et al.
Circ 2015; 132:1891-1897
Efficacy of Various Percutaneous Interventions for In-Stent Restenosis. Comprehensive Network Meta-Analysis of Randomized Controlled Trials.
A Sethi, et al.
Circ Cardiovasc Interv 2015 Online
Cholesterol Efflux Capacity and Pre-Beta-1 HDL Concentrations Are Increased in Dyslipidemic Patients Treated With Evacetrapib.
S Nicholls, et al.
JACC 2015; 66:2201-2210
Percutaneous Pulmonary Valve Implantation. Present Status and Evolving Future.
M Ansari, et al.
JACC 2015; 66:2246-2255
Possible Subclinical Leaflet Thrombosis in Bioprosthetic Aortic Valves.
R Makkar, et al.
NEJM 2015; 373:2015-2024
Polymer-Free Drug-Coated Coronary Stents in Patients at High Bleeding Risk.
P Urban, et al.
NEJM 2015; 373:2038-2047
Appropriate Use Criteria for Coronary Revascularization and Trends in Utilization, Patient Selection, and Appropriateness of Percutaneous Coronary Intervention.
N Desai, et al.
JAMA 2015; 314:2045-2053
Enhanced Cardiac Regenerative Ability of Stem Cells After Ischemia-Reperfusion Injury. Role of Human CD34+ Cells Deficient in MicroRNA-377.
D Joladarashi, et al.
JAMA 2015; 314:1832-1843
Spironolactone Versus Placebo, Bisoprolol, and Doxazosin to Determine the Optimal Treatment for Drug-Resistant Hypertension (PATHWAY-2): A Randomised, Double-Blind, Crossover Trial.
B Williams, et al.
The Lancet 2015; 386:2059-2068
Skin Antisepsis With Chlorhexidine–Alcohol Versus Povidone Iodine–Alcohol, With and Without Skin Scrubbing, for Prevention of Intravascular-Catheter-Related Infection (CLEAN): An Open-Label, Multicentre, Randomised, Controlled, Two-by-Two Factorial Trial.
O Mimoz, et al.
The Lancet 2015; 386:2069-2077

Poll Archives

Marc P. Bonaca, MD, MPH
Mark J. Eisenberg, M.D
Justin A. Ezekowitz, M.D
Myeong-Ki Hong, MD. PhD
DAPT Study
Robert W. Yeh, M.D
A Network Meta-Analysis
Michael J. Lipinski, M.D
Mark Crowther, MD, MSc, FRCPC
Gender Disparities - TAVR
Michael A. Gaglia, Jr., M.D
Geeta Gulati1, M.D
The Impact of Prior Stroke on the Outcome of Patients with Severe Aortic Stenosis Undergoing TAVR
Romain Didier, M.D
The PCSK9 Inhibitor Revolution
Norman E. Lepor, MD, FACC
Paul K. Whelton, MB, MD, MSc

The ABSORB III trial
Dean J. Kereiakes, MD
ABSORB China Trial
Run-Lin Gao, MD
Bernard Chevalier, MD
Michael Haude, MD
Giora Weisz, MD
Jose PS Henriques, MD
TOTAL: One-Year Outcomes
Sanjit S. Jolly, MD
Effect of Thrombus Aspiration in Patients With Myocardial Infarction Presenting Late After Symptom Onset
Steffen Desch, MD
Mark A. Hlatky, MD
Philip M. Urban, MD
Tuxedo: One Year Clinical Results
Upendra Kaul, MD
Bo Xu, MD
IN.PACT SFA: Two-Year Outcomes
John Laird, MD
Thierry Lefevre, MD
SAPIEN 3: One-Year Outcomes
Howard C. Herrmann, MD
John D. Carroll
Evaluation of Initial Surgical Versus Conservative Strategies in Patients With Asymptomatic Severe Aortic Stenosis:
Tomohiko Taniguchi, MD
1-Year Results from the PARTNER II Valve-in-Valve Registry
Danny Dvir, MD
1 year results of the TOTAL trial
TOTAL Investigators
RevElution Clinical Trial
Stephen G. Worthley, MBBS, PhD
CoreValve Data
Jeffrey J. Popma, MD
TWENTE Five-Year Outcomes
Clemens von Birgelen, MD, PhD
The Nordic-Baltic Bifurcation Study III
Matti Niemela, MD
Cheol Woong Yu1, MD, PhD
Pivotal Trial
James B. Hermiller Jr, MD
Neointimal Modification with Scoring-Balloon and Efficacy of Drug-Coated Balloon Therapy in Patients with Restenosis in Drug-Eluting Coronary Stents
Robert A. Byrne, MD
Alignment of DNR Status with Patients Likelihood of Favorable Neurological Survival after In-hospital Cardiac Arrest
Timothy Fendler, MD, MS
A serial multivessel OCT study
Lorenz Raber, MD, MS

Live Case Demonstration from Kusatsu Heart Center
Osamu Hatoh, MD
Treating CTO via Radial?
Richard R. Heuser, MD
Patient Selection for CTO Recanalization: What Are the Appropriate Criteria?
Tarek Helmy, MD
Treating CTOs: Is There Enough Evidence-Based Data or do We Need Further Randomized Clinical Trials?
Gerald S. Werner, MD, PhD
Indication for CTO PCI: Clinical Rationale and Appropriateness
J. Aaron Grantham, MD

MedStar Heart & Vascular Institute Granted an IDE to Initiate a Transcatheter Aortic Valve Replacement Study for Patients With Symptomatic Aortic Stenosis at Low Risk for Surgical Mortality


FDA Approves COBRA-REDUCE Trial for CeloNova’s Cobra PzF Stent System

Miracor Medical Systems Launches PICSO Impulse System in Asia

St. Jude Medical’s 27-mm and 29-mm Portico TAVR Valves Gain CE Mark Approval

Avinger Receives Financing to Support Launch of Pantheris

pToWin Assesses Phenox’s pConus Bifurcation Aneurysm Device in Wide-Neck Intracranial Aneurysms

FDA Approves Cook’s Zenith Alpha Thoracic Graft

Medtronic’s Arc Support Catheter Launched for Solitaire Stent Retriever in Acute Ischemic Stroke Treatment

CE mark for 27mm and 29mm of Portico TAVI valves

First Patient Enrolled in Phase 4 of AUGUSTUS Trial to Evaluate Safety of Eliquis

Medicure Seeks STEMI Indication for Aggrastat in United States

Nipro to Acquire Infraredx

CeloNova’s e-COBRA Clinical Registry Begins Enrollment in France

Valtech’s Cardioband Mitral Reconstruction System Receives CE Mark Approval for TMVR

US FDA approves expanded indication for BRILINTA to include long-term use in patients with a history of heart attack

Gore Unveils Q50® PLUS Stent Graft Balloon Catheter

Proteon Therapeutics Announces Top-Line Results From Phase 1 Study of Investigational Drug Vonapanitase in Patients With Symptomatic Peripheral Artery Disease

TriVascular Announces First Patient Enrolled in the LUCY Study

Boston Scientific Announces FDA Approval of Innova™ Vascular Self-Expanding Stent System

QualiMed's QBX 5-F Balloon-Expandable Stent System Launched in Europe
Angiomyogenesis & Cell Therapy
Carotid Interventions

Home | CRT2015 | CardioTube | Interesting Cases | Trials | Weekly Poll Archive | Newsletter Archive | Login

Copyright © 2015, CRTONLINE - About / Contact Us. All rights reserved. Privacy Policy
Powered by Multiweb